HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: The role of HLA-C in disease prognosis

Immunogenetics

Volumn 57, Issue 12, 2006, Pages 926-933

  Campillo, José A ^a   Martínez Escribano, Jorge A ^a   Muro, Manuel ^a   Moya Quiles, Rosa ^a   Marín, Luis A ^a   Montes Ares, Olga ^a   Guerra, Natalia ^a   Sánchez Pedreño, Paloma ^a   Frías, José F ^a   Lozano, José A ^b   García Alonso, Ana M ^a   Álvarez López, M Rocío ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

HLA; Melanoma; Sentinel lymph node metastasis; Tumor thickness; Ulceration of primary lesion

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; OLIGONUCLEOTIDE;

ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ETHNOLOGY; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HOMOZYGOSITY; HUMAN; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SKIN CANCER; SPAIN; TUMOR VOLUME; ULCER;

CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENES, MHC CLASS I; GENES, MHC CLASS II; HLA-C ANTIGENS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; PHENOTYPE; PROGNOSIS; SKIN NEOPLASMS; SPAIN;

EID: 31844434660     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-005-0065-2     Document Type: Article

References (51)

1. Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ cells, and antigen-specific CTL. J Immunol 160:5239-5245
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Feming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
3. Barger BO, Acton RT, Soong SJ, Roseman J, Balch C (1982) Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 42:4276-4279
4. Bateman AC, Turner SJ, Theaker JM, Howell WM (1998) HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 52:67-73
5. Benlalam H, Labarrière N, Linard B, Derre L, Diez E, Pandolfino MC, Bonneville M, Jotereau F (2001) Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotheraphy. Eur J Immunol 31:2007-2015
6. Boon T, Gajewski FT, Coulie PG (1995) From defined human tumor antigens to effective immunization. Immunol Today 16:334-336
7. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expresion in human tumor tissues. Cancer Immunol Immunother 52:1-9
8. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, Herrero R, Rodriguez AC, Kurman R, Mortel R, Shuartz P, Glass A, Hildesheim A (2005) Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med 201:1069-1075
9. Colonna M, Borsellingo G, Falco M, Ferrara GB, Strominger JL (1993) HLA-C is the inhibitory ligand that determined dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 90:12000-12004
10. Fan QR, Long EO, Wiley DC (2001) Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2:452-460
11. Ghiorzo P, Bianchi Scar GB (2003) Genetics of melanoma susceptibility. Forum 13:114-126
12. Herman J, Van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG (1996) A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 43:377-383
13. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CWG, Carrington M, Trowsdale J, Moffett A (2004) Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 200:957-965
14. Huard B, Karlsson L (2000) A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol 30:1665-1675
15. Igarashi T, Wynberg J, Srinivasan R, Becknell B, Phillip McCoy J Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170-177
16. Jovic V, Konjevic G, Radulovic S, Jelic S, Spuzic I (2001) Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori 87:324-329
17. Kageshita T, Naruse T, Hirai S, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H, Ono T (1996) HLA class I antigens in Japanese patients with melanoma. J Immunother Emphasis Tumor Immunol 19:428-432
18. Kageshita T, Naruse T, Hirai S, Ono T, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H (1997) Molecular genetic analysis of HLA class II alleles in Japanese patients with melanoma. Tissue Antigens 49:466-470
19. Kawasaki ES (1990) Sample preparation from blood, cells, and other fluids. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds) PCR protocols: a guide methods and application. Academic, New York
20. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Chen J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872-874
21. Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A (2001) In vitro anti-tumor activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer 85:741-746
22. Lanier LL (1997) Natural killer cells: from no receptors to too many. Immunity 6:371-378
23. Lee JE, Reveille JD, Ross MI, Platsoucas CD (1994) HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 59:510-513
24. Lee PP, Yee C, Savage PA, Fong L, Brokstedt D, Weber J, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685
25. Lombardi ML, Mercuro O, Pirozzi G, Ionna F, Lombarda V, Mozzillo N, Manzo C (1998) Molecular analysis of HLA-DRB1 and DQB1 polymorphism in Italian melanoma patients. J Immunother 21:435-439
26. Lulli P, Grammatico P, Brioli G, Catricala C, Morellini M, Roccella M, Mariani B, Pennesi G, Roccella F, Cappellacci S, Trabace S (1998) HLA-DR and -DQ alleles in Italian patients with melanoma. Tissue Antigens 51:276-280
27. Luongo V, Pirozzi G, Caraco C, Errico S, de Angelis F, Celentano E, Paino F, Chiofalo MG, Luongo M, Mozzillo N, Lombardi ML (2004) HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens 64:84-87
28. Mandelboim O, Reyburn HT, Valés-Gómez M, Pazmany L, Colonna M, Borsellino G, Strominger JL (1996) Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 184:913-922
29. Martin MP, Nelson G, Lee J-H, Pellett F, Gao X, Wade J, Wilson MJ, Trowsdale J, Gladman D, Carrington M (2002) Susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169:2818-2822
30. Mueller-Eckhardt G, Schendel DJ, Hundeiker M, Riedel T, O'Neill GJ, Riethmuller G, Mueller-Echardt C (1984) Possible association between HLA-DR5 and superficial spreading melanoma (SSM). Int J Cancer 34:751-755
31. Muto M, Ohmura A, Nakano J, Yamazaki N, Yamamoto A, Ishihara K, Sasazuki T, Asagami C (1996) HLA class I polymorphism and the susceptibility to malignant melanoma. Tissue Antigens 47:447-449
32. Nagore E, Planelles MD, Ledesma E, Millan JM, Insa A, Oliver V, Guillen C, Fortea JM (2002) Molecular genetic analysis of HLA-DR and -DQ alleles in Spanish patients with melanoma. Acta Derm Venereol 82:90-93
33. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M (2005) Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54:172-178
34. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M (2004) Heterozygote advantage in autoimmune disease: hierarchy of protection/ susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 173:4273-4276
35. Nikitina-Zake L, Rajalingham R, Rumba I, Sanjeevi CB (2004) Killer cell immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy controls. Ann N Y Acad Sci 1037:161-169
36. Parham P (2004) NK cells lose their inhibition. Science 305:786-787
37. Rajagopalan S, Long EO (2005) Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 201:1025-1029
38. Ríos A, Rodriguez JM, Moya MR, Galindo PJ, Canteras M, Álvarez MR, Parrilla P (2004) Frequency of HLA-C alleles in differentiated thyroid carcinoma in south-eastern Spain. Cancer 100:264-269
39. Rees RC, Mian S (1999) Selective MHC expression in tumours modulates adaptive and innate antitumor responses. Cancer Immunol Immunother 48:374-381
40. Rovini D, Sacchini V, Codazzi V, Vaglini M, Illeni MT (1984) HLA antigens in malignant melanoma patients. A second study. Tumori 70:29-33
41. Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, van der Bruggen P (2001) A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 57:103-109
42. Svejgaard A, Ryder LP (1994) HLA and disease associations: detecting the strongest association. Tissue Antigens 43:18-27
43. Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton AN (1995) Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154:772-779
44. Terasaki PI, McClelland JD, Park MS, McCurdy B (1974). Microdoplet assay of human serum cytotoxins. In: Ray JG, Hare DB, Pederson PD, Kayhoe DE (eds) Manual of tissue typing techniques. Department of Health, Education and Welfare Publications, Washington, DC
45. Timonen T, Helander TS (1997) Natural killer cell-target cell interactions. Curr Opin Cell Biol 9:667-673
46. Valés-Gómez M, Reyburn HT, Erskine RA, Strominger J (1998) Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A 95:14326-14331
47. Vitale M, Sivori S, Pende D, Moretta L, Moretta A (1995) Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill normal allogeneic target cells. Proc Natl Acad Sci U S A 92:3536-3540
48. Vivier E, Anfossi N (2004) Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev 4:190-198
49. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, Boon T (1994) Two tyrosinase nonapeptides recognized HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764
50. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastastic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168-16173
51. Zennadi R, Abdel-Wahab Z, Seigler HF, Darrow TL (2001) Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol 210:96-105